CBR1 Recombinant Antibody, PE-Cy5.5 Conjugated
Product Specifications
Background
NADPH-dependent reductase with broad substrate specificity. Catalyzes the reduction of a wide variety of carbonyl compounds including quinones, prostaglandins, menadione, plus various xenobiotics. Catalyzes the reduction of the antitumor anthracyclines doxorubicin and daunorubicin to the cardiotoxic compounds doxorubicinol and daunorubicinol.
Synonyms
15 hydroxyprostaglandin dehydrogenase [NADP+]; Carbonyl reductase [NADPH] 1; CBR1; CRN; NADPH dependent carbonyl reductase 1; Prostaglandin 9 ketoreductase; SDR21C1.
Gene ID
873
Swiss Prot
P16152
Cellular Locus
Cytoplasm
Host
Rabbit
Cross Reactivity
Human
Target
CBR1
Clonality
Recombinant
Isotype
IgG
Conjugation
PE-Cy5.5
Source
KLH conjugated synthetic peptide derived from human CBR1
Applications
WB
Purification
Purified by Protein A.
Excitation Emission
488nm/694nm
Concentration
Lot dependent
Dilution
WB (1:300-5000)
Buffer
Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Modification
Unmodified
Storage Conditions
Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
Gene ID URL
873
More Discoveries
Explore Other Products
Browse additional items from our catalog
032403-ML550 100 µL
BAD, phosphorylated (S57) (Bcl2 antagonist of cell death, BAD, BBC6, BCL2L8) (MaxLight 550) discontinued
Sign In for Pricing
View Details 